0001209191-22-044905.txt : 20220808
0001209191-22-044905.hdr.sgml : 20220808
20220808203256
ACCESSION NUMBER: 0001209191-22-044905
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220804
FILED AS OF DATE: 20220808
DATE AS OF CHANGE: 20220808
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schor Chen
CENTRAL INDEX KEY: 0001340875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 221146089
MAIL ADDRESS:
STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-04
0
0001720580
Adicet Bio, Inc.
ACET
0001340875
Schor Chen
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
1
1
0
0
President & CEO
Common Stock
2022-07-06
5
G
0
E
53424
0.00
D
96000
D
Common Stock
2022-07-06
5
G
0
E
53424
0.00
A
143260
I
See Footnote
Common Stock
2022-08-04
4
A
0
48000
0.00
A
144000
D
Common Stock
2022-08-04
4
F
0
21288
18.25
D
122712
D
Common Stock
74841
I
See Footnote
Represents the transfer of shares held by the Reporting Person to The C. Schor IRRV Trust for no consideration.
Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
The Reporting Person's Form 4s filed on October 5, 2021, January 11, 2022, February 1, 2022 and February 16, 2022 inadvertently omitted the Reporting Person's indirect holdings of common stock held by The C. Schor IRRV Trust and The I. Schor IRRV Trust (the "Trusts"), both of which are irrevocable family trusts having independent trustees. There have been no changes to the holdings of the Trusts since the Form 4 filed by the Reporting Person on June 21, 2021, other than as reported on this Form 4.
/s/ Nick Harvey, Attorney-in-Fact
2022-08-08